Stifel Nicolaus Remains a Buy on Black Diamond Therapeutics (BDTX)

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Black Diamond Therapeutics (BDTXResearch Report) yesterday and set a price target of $15.00. The company’s shares closed yesterday at $5.00.

Canino covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Kura Oncology, and Merus. According to TipRanks, Canino has an average return of 5.5% and a 46.90% success rate on recommended stocks.

Currently, the analyst consensus on Black Diamond Therapeutics is a Strong Buy with an average price target of $13.50, representing a 170.00% upside. In a report released on March 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

Based on Black Diamond Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $334 thousand and a GAAP net loss of $19.41 million. In comparison, last year the company had a GAAP net loss of $21.08 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Black Diamond Therapeutics (BDTX) Company Description:

Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.